2013 2016 DEA Safety 
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. DEA and the Controlled Substances Act.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
SEPTEMBER 7, 2021
There was no testing information, no information about the manufacturer, no product safety assurance whatsoever. . Drug Enforcement Administration (DEA) recently moved to counter that argument. . DEA’s July 2021 update. And that could have a major impact on product safety. . Not a whole lot. But the U.S.
Cannabis Law Report
DECEMBER 1, 2019
Barr stated, “I am not going to go after companies that have relied on the Cole memorandum,” referring to the 2013 Obama administration policy of not enforcing marijuana prohibition in states where legalization has been established. “To Nevertheless, during his confirmation hearing in January 2019, Attorney General William P. Comm’r (T.C.
Cannabis Law Report
SEPTEMBER 23, 2019
Therefore, the AAFP advocates for further research into the overall safety and health effects of recreational use, as well as the effects of those laws on patient and societal health. The AAFP supports requirements testing current marijuana and cannabinoid products for safety, dosing, and product consistency. In the Exam Room.
Expert insights. Personalized for you.
52 
Let's personalize your content